{"id":123387,"date":"2025-08-06T10:47:12","date_gmt":"2025-08-06T10:47:12","guid":{"rendered":"https:\/\/www.europesays.com\/us\/123387\/"},"modified":"2025-08-06T10:47:12","modified_gmt":"2025-08-06T10:47:12","slug":"fulgent-genetics-inc-s-nasdaqflgt-p-s-is-on-the-mark","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/123387\/","title":{"rendered":"Fulgent Genetics, Inc.’s (NASDAQ:FLGT) P\/S Is On The Mark"},"content":{"rendered":"

\"NasdaqGM:FLGT<\/a>NasdaqGM:FLGT 1 Year Share Price vs Fair ValueExplore Fulgent Genetics’s Fair Values from the Community and select yours<\/a><\/p>\n

When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or “P\/S”) below 1x, you may consider Fulgent Genetics, Inc. <\/strong>(NASDAQ:FLGT<\/a>) as a stock to potentially avoid with its 2.1x P\/S ratio. However, the P\/S might be high for a reason and it requires further investigation to determine if it’s justified. <\/p>\n

We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.<\/a><\/p>\n

View our latest analysis for Fulgent Genetics <\/a><\/p>\n

\"ps-multiple-vs-industry\"<\/a>NasdaqGM:FLGT Price to Sales Ratio vs Industry August 6th 2025 How Fulgent Genetics Has Been Performing <\/p>\n

Recent times haven’t been great for Fulgent Genetics as its revenue has been rising slower than most other companies. Perhaps the market is expecting future revenue performance to undergo a reversal of fortunes, which has elevated the P\/S ratio. However, if this isn’t the case, investors might get caught out paying too much for the stock. <\/p>\n

If you’d like to see what analysts are forecasting going forward, you should check out our free <\/strong>report on Fulgent Genetics<\/a>. Is There Enough Revenue Growth Forecasted For Fulgent Genetics? <\/p>\n

In order to justify its P\/S ratio, Fulgent Genetics would need to produce impressive growth in excess of the industry. <\/p>\n

If we review the last year of revenue growth, the company posted a worthy increase of 4.3%. Still, lamentably revenue has fallen 67% in aggregate from three years ago, which is disappointing. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenue over that time. <\/p>\n

Shifting to the future, estimates from the three analysts covering the company suggest revenue should grow by 11% over the next year. With the industry only predicted to deliver 7.7%, the company is positioned for a stronger revenue result. <\/p>\n

With this in mind, it’s not hard to understand why Fulgent Genetics’ P\/S is high relative to its industry peers. Apparently shareholders aren’t keen to offload something that is potentially eyeing a more prosperous future. <\/p>\n

The Final Word <\/p>\n

Using the price-to-sales ratio alone to determine if you should sell your stock isn’t sensible, however it can be a practical guide to the company’s future prospects. <\/p>\n

Our look into Fulgent Genetics shows that its P\/S ratio remains high on the merit of its strong future revenues. Right now shareholders are comfortable with the P\/S as they are quite confident future revenues aren’t under threat. Unless these conditions change, they will continue to provide strong support to the share price. <\/p>\n

And what about other risks? Every company has them, and we’ve spotted 2 warning signs for Fulgent Genetics <\/strong> <\/a> (of which 1 is significant!) you should know about. <\/p>\n

If companies with solid past earnings growth is up your alley<\/strong>, you may wish to see this free<\/strong> collection of other companies with strong earnings growth and low P\/E ratios.<\/a> <\/p>\n

New: <\/strong>AI Stock Screener & Alerts<\/p>\n

Our new AI Stock Screener scans the market every day to uncover opportunities.<\/p>\n

\u2022 Dividend Powerhouses (3%+ Yield)
\u2022 Undervalued Small Caps with Insider Buying
\u2022 High growth Tech and AI Companies<\/p>\n

Or build your own from over 50 metrics.<\/p>\n

Explore Now for Free<\/a><\/p>\n

Have feedback on this article? Concerned about the content?<\/strong> Get in touch<\/strong><\/a> with us directly.<\/strong> Alternatively, email editorial-team (at) simplywallst.com.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.<\/strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n","protected":false},"excerpt":{"rendered":"NasdaqGM:FLGT 1 Year Share Price vs Fair ValueExplore Fulgent Genetics’s Fair Values from the Community and select yours…\n","protected":false},"author":3,"featured_media":123388,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[815,159,67,132,68],"class_list":{"0":"post-123387","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-science","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114981427148342687","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/123387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=123387"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/123387\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/123388"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=123387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=123387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=123387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}